局所進行膵臓がんの世界市場レポート 2025年

局所進行膵臓がん市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR10.5％で15億7,000万米ドルに成長します。予測期間の成長は、膵臓がんに対する認識の高まり、化学療法レジメンの進歩、標的療法の使用の増加、膵臓がんの罹患率の上昇、併用治療プロトコルの開発、支持療法の選択肢の改善などに起因すると考えられます。主な動向としては、免疫療法の進歩、標的療法の開発、精密放射線技術の強化、画像診断の改善、低侵襲手術アプローチの採用、治療計画における人工知能の統合、併用療法戦略の進展などが挙げられます。

タバコの消費量の増加は、今後数年間の局所進行膵臓がん市場の成長に寄与すると予想されます。植物の葉に由来するタバコは、タバコや葉巻などの製品に一般的に使用され、がんや心臓病などの深刻な健康状態に関連する中毒性の高い物質であるニコチンを含んでいます。入手しやすさ、手ごろな価格、たばこのマーケティング、特定の地域における社会的受容、ストレスに起因する喫煙など、いくつかの要因がたばこ使用の増加を後押ししています。タバコの消費は、膵臓悪性腫瘍の発生率の上昇につながるため、局所進行膵臓がんの開発にとって重要な危険因子です。例えば、2024年1月、喫煙の蔓延を終わらせることを目的とする米国の非営利団体Global Action to End Smokingによると、2022年に米国でタバコを使用していた成人は約6,290万人で、これは世界的にみても4番目に高く、南北南北アメリカでは最も高いです。さらに、米国成人の約11.5％（2,830万人）がタバコを吸っており、女性（10.1％）に比べて男性（13.1％）の有病率が高いです。その結果、タバコ消費の増加が局所進行膵臓がん市場の拡大を牽引しています。

局所進行膵臓がん市場の主要企業は、治療の選択肢を増やし、患者の予後を改善し、この攻撃的な疾患に関連するアンメット・メディカル・ニーズに対応するため、希少疾病用医薬品などの革新的な製品の開発を優先しています。希少疾病用医薬品は、限られた人口に影響を及ぼす希少疾病を治療するために特別に開発された医薬品であり、その開発を促進するために、税制優遇措置や市場独占権などの規制上の優遇措置が設けられています。例えば、2025年1月、米国のバイオ医薬品会社であるアクチュエート・セラピューティクス社は、新規のGSK-3B阻害剤である同社の医薬品Elraglusibが、局所進行膵臓がんの可能性のある膵管腺がん（PDAC）の治療薬として、欧州医薬品庁（EMA）と米国食品医薬品局（FDA）の両方から希少疾病用医薬品の指定を受けたと発表しました。この指定は、特に転移性PDAC患者における臨床的な有意な改善と抗腫瘍効果を実証した有望な第2相試験の結果を受けて、この重篤ながんの治療における重大なギャップを解決する可能性を強調するものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界局所進行膵臓がんPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の局所進行膵臓がん市場：成長率分析
• 世界の局所進行膵臓がん市場の実績：規模と成長, 2019-2024
• 世界の局所進行膵臓がん市場の予測：規模と成長, 2024-2029, 2034F
• 世界局所進行膵臓がん総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の局所進行膵臓がん市場：セラピー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法
• 免疫療法
• 放射線治療
• 手術
• 世界の局所進行膵臓がん市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射剤
• その他の投与経路
• 世界の局所進行膵臓がん市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• 調査機関
• その他のエンドユーザー
• 世界の局所進行膵臓がん市場化学療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ゲムシタビンベースの化学療法
• フォルフィリノックス化学療法
• 世界の局所進行膵臓がん市場免疫療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫チェックポイント阻害剤
• がんワクチン
• 世界の局所進行膵臓がん市場放射線治療の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 外部放射線療法
• 定位放射線治療（SBRT）
• 世界の局所進行膵臓がん市場、手術の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 膵頭十二指腸切除術（ホイップル手術）
• 膵体尾部切除術
• 膵臓全摘出術

第7章 地域別・国別分析

• 世界の局所進行膵臓がん市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の局所進行膵臓がん市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 局所進行膵臓がん市場：競合情勢
• 局所進行膵臓がん市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bristol-Myers Squibb Company
• AstraZeneca plc
• Abbott Laboratories
• Novartis AG
• GSK plc
• Ipsen Biopharmaceuticals Inc.
• Lupin Limited
• NovoCure Limited
• Theratechnologies Inc.
• XBiotech
• Prestige Biopharma
• OSE Immunotherapeutics
• Helix Biopharma Corporation
• Fawn Incorporation
• Eli Lilly and Co

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 局所進行膵臓がん市場2029：新たな機会を提供する国
• 局所進行膵臓がん市場2029：新たな機会を提供するセグメント
• 局所進行膵臓がん市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Locally advanced pancreatic cancer (LAPC) is a stage of pancreatic cancer in which the tumor remains confined to the pancreas and surrounding tissues but has not metastasized to distant organs. Due to its involvement with vital blood vessels or nearby structures, LAPC is typically not suitable for surgical removal.

The primary treatment options for locally advanced pancreatic cancer include chemotherapy, immunotherapy, radiation therapy, and surgery. Chemotherapy uses drugs to destroy cancer cells or inhibit their growth. These therapies can be administered through various routes, including oral, injectable, and others, and are utilized in hospitals, specialty clinics, research institutes, and other healthcare settings.

The locally advanced pancreatic cancer market research report is one of a series of new reports from The Business Research Company that provides locally advanced pancreatic cancer market statistics, including the locally advanced pancreatic cancer industry's global market size, regional shares, competitors with a locally advanced pancreatic cancer market share, detailed locally advanced pancreatic cancer market segments, market trends and opportunities, and any further data you may need to thrive in the locally advanced pancreatic cancer industry. This locally advanced pancreatic cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The locally advanced pancreatic cancer market size has grown rapidly in recent years. It will grow from $0.95 billion in 2024 to $1.05 billion in 2025 at a compound annual growth rate (CAGR) of 10.9%. The growth in the historic period can be attributed to increased awareness of pancreatic cancer, advancements in chemotherapy regimens, the growing use of targeted therapies, a rising incidence of pancreatic cancer, the development of combination treatment protocols, and enhanced supportive care options.

The locally advanced pancreatic cancer market size is expected to see rapid growth in the next few years. It will grow to $1.57 billion in 2029 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to increasing awareness of pancreatic cancer, advancements in chemotherapy regimens, the growing use of targeted therapies, a rising incidence of pancreatic cancer, the development of combination treatment protocols, and improved supportive care options. Major trends include advancements in immunotherapy, the development of targeted therapies, enhanced precision radiation techniques, improvements in diagnostic imaging, the adoption of minimally invasive surgical approaches, the integration of artificial intelligence in treatment planning, and progress in combination therapy strategies.

The rising consumption of tobacco is expected to contribute to the growth of the locally advanced pancreatic cancer market in the coming years. Tobacco, derived from plant leaves, is commonly used in products such as cigarettes and cigars and contains nicotine, a highly addictive substance linked to severe health conditions such as cancer and heart disease. Several factors, including easy access, affordability, tobacco marketing, social acceptance in certain regions, and stress-related smoking, have driven the increase in tobacco use. Tobacco consumption is a significant risk factor for the development of locally advanced pancreatic cancer, as it leads to a higher incidence of pancreatic malignancies. For example, in January 2024, according to Global Action to End Smoking, a US-based non-profit organization dedicated to ending the smoking epidemic, approximately 62.9 million adults in the U.S. used tobacco in 2022, making it the fourth-highest globally and the highest in the Americas. Additionally, around 11.5% of U.S. adults (28.3 million) smoked cigarettes, with a higher prevalence among males (13.1%) compared to females (10.1%). Consequently, the increase in tobacco consumption is driving the expansion of the locally advanced pancreatic cancer market.

Leading companies in the locally advanced pancreatic cancer market are prioritizing the development of innovative products, such as orphan drugs, to enhance treatment options, improve patient outcomes, and address the unmet medical needs associated with this aggressive disease. Orphan drugs are specifically designed to treat rare conditions affecting a limited population and are supported by regulatory incentives, including tax benefits and market exclusivity, to encourage their development. For instance, in January 2025, Actuate Therapeutics Inc., a US-based biopharmaceutical company, announced that its drug Elraglusib, a novel GSK-3B inhibitor, had received Orphan Drug Designation from both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for the treatment of pancreatic ductal adenocarcinoma (PDAC), a potential form of locally advanced pancreatic cancer. This designation underscores its potential to address a critical gap in treating this severe cancer, particularly following promising Phase 2 trial results that demonstrated significant clinical improvements and anti-tumor effects in patients with metastatic PDAC.

In June 2024, AstraZeneca Plc, a UK-based pharmaceutical company, acquired Fusion Pharmaceuticals Inc. for $2.5 billion. This acquisition is intended to strengthen AstraZeneca's oncology portfolio by incorporating advanced radiopharmaceuticals such as FPI-2265, enhancing research and development and manufacturing capabilities, and accelerating the transition to targeted cancer therapies while expanding its presence in Canada. Fusion Pharmaceuticals Inc. is a Canada-based biotechnology company that focuses on developing targeted therapies for various types of cancer, including pancreatic cancer.

Major players in the locally advanced pancreatic cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, AbbVie Inc., Bayer Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GSK plc, Ipsen Biopharmaceuticals Inc., Lupin Limited, NovoCure Limited, Theratechnologies Inc., XBiotech, Prestige Biopharma, OSE Immunotherapeutics, Helix Biopharma Corporation, Fawn Incorporation, Eli Lilly and Co.

North America was the largest region in the locally advanced pancreatic cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in locally advanced pancreatic cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the locally advanced pancreatic cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The locally advanced pancreatic cancer market consists of revenues earned by entities by providing services such as chemoradiation, palliative care, targeted therapy, and clinical trials. The market value includes the value of related goods sold by the service provider or included within the service offering. The locally advanced pancreatic cancer market also includes sales of CT scanners, MRI machines, brachytherapy systems, needle biopsy devices, and hemodynamic monitors. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Locally Advanced Pancreatic Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on locally advanced pancreatic cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for locally advanced pancreatic cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The locally advanced pancreatic cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapy: Chemotherapy; Immunotherapy; Radiation Therapy; Surgery
• 2) By Route Of Administration: Oral; Injectables; Other Route Of Administrations
• 3) By End-User: Hospital; Specialty Clinics; Research Institutions; Other End-Users
• Subsegments:
• 1) By Chemotherapy: Gemcitabine-based Chemotherapy; FOLFIRINOX Chemotherapy
• 2) By Immunotherapy: Immune Checkpoint Inhibitors; Cancer Vaccines
• 3) By Radiation Therapy: External Beam Radiation Therapy; Stereotactic Body Radiation Therapy (SBRT)
• 4) By Surgery: Pancreaticoduodenectomy (Whipple Procedure); Distal Pancreatectomy; Total Pancreatectomy
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck KGaA; AbbVie Inc.; Bayer Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Locally Advanced Pancreatic Cancer Market Characteristics

3. Locally Advanced Pancreatic Cancer Market Trends And Strategies

4. Locally Advanced Pancreatic Cancer Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Locally Advanced Pancreatic Cancer Growth Analysis And Strategic Analysis Framework

• 5.1. Global Locally Advanced Pancreatic Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Locally Advanced Pancreatic Cancer Market Growth Rate Analysis
• 5.4. Global Locally Advanced Pancreatic Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Locally Advanced Pancreatic Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Locally Advanced Pancreatic Cancer Total Addressable Market (TAM)

6. Locally Advanced Pancreatic Cancer Market Segmentation

• 6.1. Global Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Immunotherapy
• Radiation Therapy
• Surgery
• 6.2. Global Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectables
• Other Route Of Administrations
• 6.3. Global Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Specialty Clinics
• Research Institutions
• Other End-Users
• 6.4. Global Locally Advanced Pancreatic Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gemcitabine-based Chemotherapy
• FOLFIRINOX Chemotherapy
• 6.5. Global Locally Advanced Pancreatic Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immune Checkpoint Inhibitors
• Cancer Vaccines
• 6.6. Global Locally Advanced Pancreatic Cancer Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• External Beam Radiation Therapy
• Stereotactic Body Radiation Therapy (SBRT)
• 6.7. Global Locally Advanced Pancreatic Cancer Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pancreaticoduodenectomy (Whipple Procedure)
• Distal Pancreatectomy
• Total Pancreatectomy

7. Locally Advanced Pancreatic Cancer Market Regional And Country Analysis

• 7.1. Global Locally Advanced Pancreatic Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Locally Advanced Pancreatic Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Locally Advanced Pancreatic Cancer Market

• 8.1. Asia-Pacific Locally Advanced Pancreatic Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Locally Advanced Pancreatic Cancer Market

• 9.1. China Locally Advanced Pancreatic Cancer Market Overview
• 9.2. China Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Locally Advanced Pancreatic Cancer Market

• 10.1. India Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Locally Advanced Pancreatic Cancer Market

• 11.1. Japan Locally Advanced Pancreatic Cancer Market Overview
• 11.2. Japan Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Locally Advanced Pancreatic Cancer Market

• 12.1. Australia Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Locally Advanced Pancreatic Cancer Market

• 13.1. Indonesia Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Locally Advanced Pancreatic Cancer Market

• 14.1. South Korea Locally Advanced Pancreatic Cancer Market Overview
• 14.2. South Korea Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Locally Advanced Pancreatic Cancer Market

• 15.1. Western Europe Locally Advanced Pancreatic Cancer Market Overview
• 15.2. Western Europe Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Locally Advanced Pancreatic Cancer Market

• 16.1. UK Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Locally Advanced Pancreatic Cancer Market

• 17.1. Germany Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Locally Advanced Pancreatic Cancer Market

• 18.1. France Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Locally Advanced Pancreatic Cancer Market

• 19.1. Italy Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Locally Advanced Pancreatic Cancer Market

• 20.1. Spain Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Locally Advanced Pancreatic Cancer Market

• 21.1. Eastern Europe Locally Advanced Pancreatic Cancer Market Overview
• 21.2. Eastern Europe Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Locally Advanced Pancreatic Cancer Market

• 22.1. Russia Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Locally Advanced Pancreatic Cancer Market

• 23.1. North America Locally Advanced Pancreatic Cancer Market Overview
• 23.2. North America Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Locally Advanced Pancreatic Cancer Market

• 24.1. USA Locally Advanced Pancreatic Cancer Market Overview
• 24.2. USA Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Locally Advanced Pancreatic Cancer Market

• 25.1. Canada Locally Advanced Pancreatic Cancer Market Overview
• 25.2. Canada Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Locally Advanced Pancreatic Cancer Market

• 26.1. South America Locally Advanced Pancreatic Cancer Market Overview
• 26.2. South America Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Locally Advanced Pancreatic Cancer Market

• 27.1. Brazil Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Locally Advanced Pancreatic Cancer Market

• 28.1. Middle East Locally Advanced Pancreatic Cancer Market Overview
• 28.2. Middle East Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Locally Advanced Pancreatic Cancer Market

• 29.1. Africa Locally Advanced Pancreatic Cancer Market Overview
• 29.2. Africa Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Locally Advanced Pancreatic Cancer Market Competitive Landscape And Company Profiles

• 30.1. Locally Advanced Pancreatic Cancer Market Competitive Landscape
• 30.2. Locally Advanced Pancreatic Cancer Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Locally Advanced Pancreatic Cancer Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company
• 31.2. AstraZeneca plc
• 31.3. Abbott Laboratories
• 31.4. Novartis AG
• 31.5. GSK plc
• 31.6. Ipsen Biopharmaceuticals Inc.
• 31.7. Lupin Limited
• 31.8. NovoCure Limited
• 31.9. Theratechnologies Inc.
• 31.10. XBiotech
• 31.11. Prestige Biopharma
• 31.12. OSE Immunotherapeutics
• 31.13. Helix Biopharma Corporation
• 31.14. Fawn Incorporation
• 31.15. Eli Lilly and Co

32. Global Locally Advanced Pancreatic Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Locally Advanced Pancreatic Cancer Market

34. Recent Developments In The Locally Advanced Pancreatic Cancer Market

35. Locally Advanced Pancreatic Cancer Market High Potential Countries, Segments and Strategies

• 35.1 Locally Advanced Pancreatic Cancer Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Locally Advanced Pancreatic Cancer Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Locally Advanced Pancreatic Cancer Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer